Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference

Core Insights - Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for AL Amyloidosis and other serious diseases [3] - The company will present and host institutional investor meetings at the 37th Annual Piper Sandler Healthcare Conference from December 2-4, 2025 [1] - ImmixBio's lead candidate is NXC-201, a BCMA-targeted CAR-T cell therapy, which has met its primary endpoint in an interim study [3] Company Overview - Immix Biopharma, Inc. (Nasdaq: IMMX) is engaged in developing cell therapies specifically for AL Amyloidosis [3] - The lead product candidate, NXC-201, features a "digital filter" to minimize non-specific activation and is currently being evaluated in a multi-center study in the U.S. [3] - NXC-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and Orphan Drug Designation (ODD) from both the FDA and EMA [3] Conference Details - The company will be available for one-on-one meetings during the Piper Sandler Healthcare Conference, and interested investors can contact their Piper Sandler representative for arrangements [2] - A replay of the presentation will be accessible on the Immix website under the Investors section [2]